Literature DB >> 33822597

In Vitro Selection of Macrocyclic d/l-Hybrid Peptides against Human EGFR.

Sayaka Imanishi1, Takayuki Katoh1, Yizhen Yin1, Mituhiro Yamada1, Marina Kawai1, Hiroaki Suga1.   

Abstract

d/l-Hybrid peptides are an attractive class of molecular modality because they are able to exhibit high proteolytic stability and unique structural diversity which cannot be accessed by those consisting of only proteinogenic l-amino acids. Despite such an expectation, it has not been possible to devise de novo d/l-hybrid peptides capable of disrupting the function of a protein target(s) due to the lack of an effective method that reliably constructs a highly diverse library and screens active species. Here we report for the first time construction of a library consisting of 1012 members of macrocyclic d/l-hybrid peptides containing five kinds of d-amino acids and performance of the RaPID selection against human EGFR as a showcase to uncover PPI (protein-protein interaction) inhibitors.

Entities:  

Year:  2021        PMID: 33822597     DOI: 10.1021/jacs.1c02593

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  3 in total

1.  In Vitro Selection of Macrocyclic α/β3-Peptides against Human EGFR.

Authors:  Risa Wakabayashi; Marina Kawai; Takayuki Katoh; Hiroaki Suga
Journal:  J Am Chem Soc       Date:  2022-09-29       Impact factor: 16.383

Review 2.  Peptide/protein-based macrocycles: from biological synthesis to biomedical applications.

Authors:  Wen-Hao Wu; Jianwen Guo; Longshuai Zhang; Wen-Bin Zhang; Weiping Gao
Journal:  RSC Chem Biol       Date:  2022-06-09

Review 3.  Peptide-Based Inhibitors for SARS-CoV-2 and SARS-CoV.

Authors:  Disha Panchal; Jeena Kataria; Kamiya Patel; Kaytlyn Crowe; Varun Pai; Abdul-Rahman Azizogli; Neil Kadian; Sreya Sanyal; Abhishek Roy; Joseph Dodd-O; Amanda M Acevedo-Jake; Vivek A Kumar
Journal:  Adv Ther (Weinh)       Date:  2021-08-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.